375 related articles for article (PubMed ID: 24157549)
1. A three-stage biophysical screening cascade for fragment-based drug discovery.
Mashalidis EH; Śledź P; Lang S; Abell C
Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometry for fragment screening.
Chan DS; Whitehouse AJ; Coyne AG; Abell C
Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
[TBL] [Abstract][Full Text] [Related]
3. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery.
Silvestre HL; Blundell TL; Abell C; Ciulli A
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):12984-9. PubMed ID: 23872845
[TBL] [Abstract][Full Text] [Related]
4. Biophysical screening for the discovery of small-molecule ligands.
Ciulli A
Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
[TBL] [Abstract][Full Text] [Related]
5. Experiences in fragment-based lead discovery.
Hubbard RE; Murray JB
Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
[TBL] [Abstract][Full Text] [Related]
6. Counting on Fragment Based Drug Design Approach for Drug Discovery.
Kashyap A; Singh PK; Silakari O
Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based drug discovery using rational design.
Jhoti H
Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
[TBL] [Abstract][Full Text] [Related]
8. Fragment based drug design: from experimental to computational approaches.
Kumar A; Voet A; Zhang KY
Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
[TBL] [Abstract][Full Text] [Related]
9. Fragment-based drug discovery and its application to challenging drug targets.
Price AJ; Howard S; Cons BD
Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
[TBL] [Abstract][Full Text] [Related]
10. A Novel NMR-Based Protocol to Screen Ultralow Molecular Weight Fragments.
Favaro A; Sturlese M
J Med Chem; 2024 Mar; 67(5):3874-3884. PubMed ID: 38426508
[TBL] [Abstract][Full Text] [Related]
11. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
[TBL] [Abstract][Full Text] [Related]
12. Hit-to-Lead: Hit Validation and Assessment.
Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
[TBL] [Abstract][Full Text] [Related]
13. Practical aspects of NMR-based fragment screening.
Lepre CA
Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
Han B; Ahn HC
Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
[TBL] [Abstract][Full Text] [Related]
15. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
16. Fragments: where are we now?
Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
[TBL] [Abstract][Full Text] [Related]
17. [Progress in the fragment-based drug discovery].
Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
[TBL] [Abstract][Full Text] [Related]
18. Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics.
Lau WF; Withka JM; Hepworth D; Magee TV; Du YJ; Bakken GA; Miller MD; Hendsch ZS; Thanabal V; Kolodziej SA; Xing L; Hu Q; Narasimhan LS; Love R; Charlton ME; Hughes S; van Hoorn WP; Mills JE
J Comput Aided Mol Des; 2011 Jul; 25(7):621-36. PubMed ID: 21604056
[TBL] [Abstract][Full Text] [Related]
19. NMR characterization of weak interactions between RhoGDI2 and fragment screening hits.
Liu J; Gao J; Li F; Ma R; Wei Q; Wang A; Wu J; Ruan K
Biochim Biophys Acta Gen Subj; 2017 Jan; 1861(1 Pt A):3061-3070. PubMed ID: 27721047
[TBL] [Abstract][Full Text] [Related]
20. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
